117 related articles for article (PubMed ID: 21659356)
1. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T; Volin L; Beelen DW; Trenschel R; Finke J; Schnitzler M; Holowiecki J; Giebel S; Markiewicz M; Uharek L; Blau IW; Kienast J; Stelljes M; Larsson K; Zander AR; Gramatzki M; Repp R; Einsele H; Stuhler G; Baumgart J; Mylius HA; Pichlmeier U; Freund M; Casper J
Haematologica; 2011 Sep; 96(9):1344-50. PubMed ID: 21659356
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
3. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.
Saglio F; Pagliara D; Zecca M; Balduzzi A; Cattoni A; Prete A; Tambaro FP; Faraci M; Calore E; Locatelli F; Fagioli F;
Transplant Cell Ther; 2024 Apr; 30(4):433.e1-433.e10. PubMed ID: 38176654
[TBL] [Abstract][Full Text] [Related]
5. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study.
Pasic I; Moya TA; Remberger M; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38648898
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Melphalan Dose in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning.
Kurosawa S; Shimomura Y; Itonaga H; Katayama Y; Onizuka M; Tanaka M; Kobayashi H; Ozawa Y; Sawa M; Kanda J; Doki N; Fujisawa S; Uchida N; Fukuda T; Atsuta Y; Ishiyama K
Transplant Cell Ther; 2024 May; 30(5):510.e1-510.e10. PubMed ID: 38331193
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.
Pai AA; Mohanan E; Panetta JC; Kulkarni UP; Illangeswaran RSS; Balakrishnan B; Jayaraman A; Edison ES; Lakshmi KM; Devasia AJ; Fouzia NA; Korula A; Abraham A; George B; Srivastava A; Mathews V; Standing JF; Balasubramanian P
Clin Pharmacol Ther; 2024 Jan; 115(1):116-125. PubMed ID: 37846495
[TBL] [Abstract][Full Text] [Related]
9. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
Gagelmann N; Schuh C; Flossdorf S; Kunadt D; Stelljes M; Blau IW; Brecht A; Bethge W; Schroeder T; Wulf G; Sala E; Bug G; Fleischhauer K; Kröger N;
Am J Hematol; 2024 May; ():. PubMed ID: 38742955
[TBL] [Abstract][Full Text] [Related]
10. Donor germ-line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
Auer PL; Farazi M; Zhang T; Dong J; Bolon YT; Spellman SR; Saber W
Am J Hematol; 2024 Apr; 99(4):770-773. PubMed ID: 38339773
[TBL] [Abstract][Full Text] [Related]
11. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
Gregorio C; Spreafico M; D'Amico S; Sauta E; Asti G; Lanino L; Tentori CA; Platzbecker U; Haferlach T; Diez-Campelo M; Fenaux P; Komrokji R; Della Porta MG; Ieva F
JCO Clin Cancer Inform; 2024 May; 8():e2300205. PubMed ID: 38723213
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.
Gurnari C; Koster L; Baaij L; Heiblig M; Yakoub-Agha I; Collin M; Passweg J; Bulabois CE; Khan A; Loschi M; Carnevale-Schianca F; Crisà E; Caravelli D; Kuball J; Saraceni F; Olivieri A; Rambaldi A; Kulasekararaj AG; Hayden PJ; Badoglio M; Onida F; Scheid C; Franceschini F; Mekinian A; Savic S; Voso MT; Drozd-Sokolowska J; Snowden JA; Raj K; Alexander T; Robin M; Greco R; McLornan DP
Blood Adv; 2024 Mar; 8(6):1444-1448. PubMed ID: 38330178
[No Abstract] [Full Text] [Related]
13. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Fozza C
N Engl J Med; 2018 Dec; 379(24):2379. PubMed ID: 30592585
[No Abstract] [Full Text] [Related]
14. Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 May; ():. PubMed ID: 38761360
[No Abstract] [Full Text] [Related]
15. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Casper J; Holowiecki J; Trenschel R; Wandt H; Schaefer-Eckart K; Ruutu T; Volin L; Einsele H; Stuhler G; Uharek L; Blau I; Bornhaeuser M; Zander AR; Larsson K; Markiewicz M; Giebel S; Kruzel T; Mylius HA; Baumgart J; Pichlmeier U; Freund M; Beelen DW
Bone Marrow Transplant; 2012 Sep; 47(9):1171-7. PubMed ID: 22158386
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
Beelen DW; Iacobelli S; Koster L; Eikema DJ; van Biezen A; Stölzel F; Ciceri F; Bethge W; Dreger P; Wagner-Drouet EM; Reményi P; Stelljes M; Markiewicz M; McLornan DP; Yakoub-Agha I; Mohty M
Bone Marrow Transplant; 2024 May; 59(5):670-679. PubMed ID: 38383713
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
